GO TO CMA Home
GO TO Inside CMA
GO TO Advocacy and Communications
GO TO Member Services
GO TO Publications
GO TO Professional Development
GO TO Clinical Resources

GO TO What's New
GO TO Contact CMA
GO TO Web Site Search
GO TO Web Site Map



CMAJ
CMAJ - October 20, 1998JAMC - le 20 octobre 1998
Diabetes Supplement

1998 clinical practice guidelines for the management of diabetes in Canada

Supplement to CMAJ 1998;159 (8 Suppl)

© 1998 Canadian Medical Association

References
  1. Tan H, MacLean DR. Epidemiology of diabetes mellitus in Canada. Clin Invest Med 1995;18:240-6.
  2. Tan MH, Daneman D, Lau DCW, et al. Diabetes in Canada: strategies towards 2000. Toronto: Canadian Diabetes Advisory Board; 1997. p. 3.
  3. Vinicor F. Is diabetes a public health disorder? Diabetes Care 1994;17:22-7.
  4. Diabetes in America. 2nd ed. Washington: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995.
  5. Ray NF, Wills S, Thamer M. Direct and indirect costs of diabetes in the United States. Alexandria (VA): American Diabetes Association; 1993.
  6. Rubin RJ, Altman WM, Mendelson DN. Health care expenditures for people with diabetes, 1992. J Clin Endocrinol Metab 1994;78:809A-F.
  7. Diabetes Control and Complications Trial Research Group. Lifetime benefits and costs of intensive therapy as practiced in the Diabetes Control and Complications Trial. JAMA 1996;276:1409-15.
  8. Eastman RC, Javitt JJ, Herman WS, et al. Prevention strategies for noninsulin dependent diabetes mellitus: an economic perspective. In: Taylor RD, Olefsky SI, editors. Diabetes mellitus: a fundamental and clinical text. New York: Lippincott Raven; 1996. p. 621.
  9. Expert Committee of the Canadian Diabetes Advisory Board. Clinical practice guidelines for treatment of diabetes mellitus. CMAJ 1992;147:697-712.
  10. Carruthers SG, Larochelle P, Haynes RB, et al. Report of the Canadian Hypertension Society Consensus Conference: 1. Introduction. CMAJ 1993;149:289-93.
  11. Cook DJ, Guyatt GH, Laupacis A, et al. Clinical recommendations using levels of evidence for antithrombotic agents. Chest 1995;108:227s-230s.
  12. Hayward RS, Wilson MC, Tunis SR, et al. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. A. Are the recommendations valid? JAMA 1995;274:570-4.
  13. Hayward RS, Laupacis A. Initiating, conducting and maintaining guidelines development programs. CMAJ 1993;148:507-12.
  14. Wilson MC, Hayward RS, Tunis SR, et al. Users' guides to the medical literature. VIII. How to use clinical practice guidelines. B. What are the recommendations and will they help you in caring for your patients? JAMA 1995;274:1630-2.
  15. Goldbloom R, Battista RN. The periodic health examination: introduction. CMAJ 1986;134:721-3.
  16. Brown SA. Meta-analysis of diabetes patient education research: variations in intervention effects across studies. Res Nurs Health 1992;15:409-19.
  17. Brown SA. Effects of educational interventions in diabetes care: a meta-analysis of findings. Nurs Res 1988;37:223-30.
  18. Clement S. Diabetes self-management education. Diabetes Care 1995;18:1204-14.
  19. Dunn SM, Hoskins PL, Constantino M, et al. Diabetic management: the role of the diabetes center. Diabetes Rev 1994;2:389-402.
  20. Keen H. Management of non-insulin-dependent diabetes mellitus: the United Kingdom experience. Ann Intern Med 1996;124:156-9.
  21. Funnell M. Integrated approaches to the management of NIDDM patients. Diabetes Spectrum 1996;9:55-9.
  22. Greenhalgh PM. Shared care for diabetes. A systematic review. Br J Gen Pract 1994;67:1-35.
  23. Hoskins PL, Fowler PM, Constantino M, et al. Sharing the care of diabetic patients between hospital and general practitioners: Does it work? Diabetic Med 1993;10:81-6.
  24. Hurwitz B, Goodman C, Yudkin J. Prompting the clinical care of non-insulin dependent (type II) diabetic patients in an inner city area: one model of community care. BMJ 1993;306:624-30.
  25. McGill M, Molyneaux LM, Yue DK, et al. A single visit diabetes complication assessment service: a complement to diabetes management at the primary care level. Diabet Med 1993;10:366-70.
  26. Weinberger M, Kirkman MS, Samsa GP, et al. A nurse-coordinated intervention for primary care patients with non-insulin dependent diabetes mellitus: impact on glycemic control and health-related quality of life. J Gen Intern Med 1995;10:59-66.
  27. Harris MI. Medical care for patients with diabetes: epidemiologic aspects. Ann Intern Med 1996;124:117-22.
  28. Hiss RG. Barriers to care in non-insulin-dependent diabetes mellitus: the Michigan experience. Ann Intern Med 1996;124:146-8.
  29. Hiss RG, Anderson RM, Hess GE, et al. Community diabetes care: a 10-year perspective. Diabetes Care 1994;17:1124-34.
  30. Weiner JP, Parente ST, Garnick DW, et al. Variation in office-based quality: a claims-based profile of care provided to Medicare patients with diabetes. JAMA 1995;273:1503-8.
  31. D'Eramo-Melkus GA, Wylie-Rosett J, Hagan JA. Metabolic impact of education in NIDDM. Diabetes Care 1992;15:864-9.
  32. Keen H, Hall M. Saint Vincent: a new responsibility for general practitioners? Br J Gen Pract 1995;46:447-8.
  33. Starfield B. Primary care: Participants or gatekeepers? Diabetes Care 1994;17(Suppl 1):12-7.
  34. Bennett IJ, Lambert C, Hinds G, et al. Emerging standards for diabetes care from a city-wide primary care audit. Diabet Med 1994;11:489-92.
  35. Diabetes Integrated Care Evaluation Team. Integrated care for diabetes: clinical, psychosocial and economic evaluation. BMJ 1994;308:1208-12.
  36. Brown SA. Studies of educational interventions and outcomes in diabetic adults: a meta-analysis revisited. Patient Educ Couns 1990;16:189-215.
  37. Robinson N, Bush L, Protopapa LE, Yateman NA. Employers' attitudes to diabetes. Diabetic Med 1989;6:692-7.
  38. Robinson N, Bush L, Protopapa LE, Yateman NA. Employment problems and diabetes. Diabetic Med 1990;7:16-22.
  39. Petrides P, Petermann F, Heinrichs HR, et al. Coping with employment discrimination against diabetics: trends in social medicine and social psychology. Patient Educ Couns 1995;26(1-3):203-8.
  40. Diamond Project Group on Social Issues. Global regulations on diabetes treated with insulin and their operation of motor vehicles. BMJ 1993;307:250-3.
  41. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979;28:1039-57.
  42. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20:1-15.
  43. American Diabetes Association. Gestational diabetes. Diabetes Care 1998;
    21(Suppl 1):S60-1.
  44. Roman SH, Harris MI. Management of diabetes mellitus from a public health perspective. Endocrinol Metab Clin North Am 1997;26:443-74.
  45. McCance DR, Hanson RL, Charles MA, et al. Comparison of tests for glycated haemoglobin and fasting and two hour plasma glucose concentrations as diagnostic methods for diabetes. BMJ 1994;308:1323-8.
  46. Engelgau MM, Thompson TJ, Herman WH, et al. Comparison of fasting and 2-hour glucose and HbA1c levels for diagnosing diabetes: diagnostic criteria and performance revisited. Diabetes Care 1997;20:785-91.
  47. Langer O, Levy J, Brustman L, et al. Glycemic control in gestational diabetes mellitus: how tight is tight enough: small for gestational age versus large for gestational age? Am J Obstet Gynecol 1989;161:646-53.
  48. Canadian Task Force on the Periodic Health Examination. Periodic health examination, 1992 update: 1. Screening for gestational diabetes mellitus. CMAJ 1992;147:435-43.
  49. Naylor CD. Diagnosing gestational diabetes mellitus: Is the gold standard valid? Diabetes Care 1989;12:565-72.
  50. Elixhauser A, Kitzmiller JL, Weschler JM. Short-term cost benefit of pre-conception care for diabetes [letter]. Diabetes Care 1996:19:384.
  51. Kitzmiller JL, Elixhauser A, Carr S. et al. Assessment of costs and benefits of management of gestational diabetes mellitus. Diabetes Care 1998;21(Suppl 2):B123-30.
  52. Naylor CD, Sermer M, Chen E, Farine D. Selective screening for gestational diabetes mellitus. Toronto Trihospital Gestational Diabetes Project Investigators. N Engl J Med 1997;337:1591-6.
  53. Landy HJ, Gomez-Marin O, O'Sullivan MJ. Diagnosing gestational diabetes mellitus: use of a glucose screen without administering the glucose tolerance test. Obstet Gynecol 1996;87:395-400.
  54. World Health Organisation. Diabetes mellitus: report of a WHO study group. Geneva: The Organisation; Technical Report 727.
  55. Sacks DA, Greenspoon JS, Abu-Fadil S, et al. Toward universal criteria for gestational diabetes: the 75-gram glucose tolerance test in pregnancy. Am J Obstet Gynecol 1995;172:607-14.
  56. Lind T, Sutherland HW, Molsted-Pedersen L, et al. A prospective multicentre study to determine influence of pregnancy upon the 75-g oral glucose tolerance test (OGTT). In: Sutherland HW, Stowers JM, Pearson JM, editors. Carbohydrate metabolism in pregnancy and the newborn. London (UK): Springer Verlag; 1989. p. 206-26.
  57. Carpenter MW, Coustan DR. Criteria for screening tests for gestational diabetes. Am J Obstet Gynecol 1982;144:768-73.
  58. O'Sullivan JB, Mahan CM. Criteria for the oral glucose tolerance test in pregnancy. Diabetes 1964;13:278-85.
  59. Langer O, Rodriguez DA, Xenakis EM, et al. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol 1994;170:1036-47.
  60. Metzger BE, Coustan DR, Organizing Committee, et al. Summary and recommendations of the fourth internal workshop-conference on gestational diabetes. Diabetes Care 1998;21(Suppl 2):B161-7.
  61. Harris MI, Hadden WC, Knowler WC, et al. Prevalence of diabetes and impaired glucose tolerance and plasma glucose levels in US population aged 20–74 years. Diabetes 1987;36:523-34.
  62. Harris MI, Modan M. Screening for NIDDM. Why is there no national program? Diabetes Care 1994;17:440-4.
  63. Knowler WC. Screening for NIDDM: opportunities for detection, treatment, and prevention. Diabetes Care 1994;17:445-50.
  64. Charles MA, Fontbonne A, Thibult N, et al. Risk factors for NIDDM in white population. Paris prospective study. Diabetes 1991;40:796-9.
  65. Eastman RC, Cowie CC, Harris MI. Undiagnosed diabetes or impaired glucose tolerance and cardiovascular risk. Diabetes Care 1997;20:127-8.
  66. Tuomilehto J, Knowler WC, Zimmet P. Primary prevention of non-insulin-dependent diabetes mellitus. Diabetes Metab Rev 1992;8:339-53.
  67. Jarrett RJ, Keen H, Fuller JH, et al. Worsening to diabetes in men with impaired glucose tolerance ("borderline diabetes"). Diabetologia 1979;16:25-30.
  68. Keen H, Jarrett RJ, McCartney P. The ten-year follow-up of the Bedford survey (1962–1972): glucose tolerance and diabetes. Diabetologia 1982;22:73-8.
  69. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
  70. Sartor G, Schersten B, Carlstrom S, et al. Ten-year follow-up of subjects with impaired glucose tolerance: prevention of diabetes by tolbutamide and diet regulation. Diabetes 1980;29:41-9.
  71. Chiasson JL. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance. Diabet Med 1996;13:S23-4.
  72. Nolan JJ, Ludvik B, Beerdsen P, et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med 1994;331:1188-93.
  73. Norris JM, Scott FW. A meta-analysis of infant diet and insulin-dependent diabetes mellitus: do biases play a role? Epidemiology 1996;7:87-92.
  74. Elliott RB, Pilcher CC, Fergusson DM, et al. A population based strategy to prevent insulin-dependent diabetes using nicotinamide. J Pediatr Endocrinol Metab 1996;9:501-9.
  75. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of type 1 diabetes. Lancet 1993;341:927-8.
  76. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
  77. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-86.
  78. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 1997;20:614-20.
  79. Frohlich MD, Fodor G, McPherson R, et al. Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Can J Cardiol 1998;14(Suppl A):17A-21A.
  80. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab 1994;79:1659-62.
  81. Schiffrin A, Suissa S. Predicting nocturnal hypoglycemia in patients with type 1 diabetes treated with continuous subcutaneous insulin infusion. Am J Med 1987;82:1127-32.
  82. Goldstein DE, Little RR. Monitoring glycemia in diabetes: short-term assessment. Endocrinol Metab Clin North Am 1997;26:475-86.
  83. Bertrand S, Aris-Jilwan N, Reddy S, et al. Recommendations for the use of self-monitoring of blood glucose in diabetes mellitus. Can J Diabetes Care 1996;20:14-6.
  84. Terent A, Hagfall O, Cederholm U. The effect of education and self-monitoring of blood glucose on glycosylated hemoglobin in type I diabetes: a controlled 18-month trial in a representative population. Acta Med Scand 1985;217:47-53.
  85. Varner MW. Efficacy of home blood glucose monitoring in diabetic pregnancy. Am J Med 1983;75:592-6.
  86. Ward WK, Haas LB, Beard JC. A randomized, controlled comparison of instruction by a diabetes educator versus self-instruction in self-monitoring of blood glucose. Diabetes Care 1985;8:284-6.
  87. Ziegher O, Kolopp M, Louis J, et al. Self-monitoring of blood glucose and insulin dose alteration in type 1 diabetes mellitus. Diabetes Res Clin Pract 1993;21:51-9.
  88. Abraira C, Colwell JA, Nuttall FQ, et al. Veterans Affairs Cooperative Study on glycemic control and complications in type II diabetes (VA CSDM): Results of the feasibility trial. Veterans Affairs Cooperative Study in Type II Diabetes. Diabetes Care 1995;18:1113-23.
  89. Turner R, Cull C, Holman R. United Kingdom Prospective Diabetes Study 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124(1pt2):136-45.
  90. Brown SA, Upchurch S, Anding R, et al. Promoting weight loss in type II diabetes. Diabetes Care 1996;19:613-24.
  91. Wing RR, Marcus MD, Salata R, et al. Effects of a very-low-calorie diet on long-term glycemic control in obese type 2 diabetic subjects. Arch Intern Med 1991;151:1334-40.
  92. Chantelau EA, Gosseringer G, Sonnenberg GE, et al. Moderate intake of sucrose does not impair metabolic control in pump-treated diabetic out-patients. Diabetologia 1985:2:204-7.
  93. Bantle JP, Swanson JE, Thomas W, et al. Metabolic effects of dietary sucrose in type II diabetic subjects. Diabetes Care 1993;16:1301-5.
  94. Pate RR, Pratt M, Blair SN, et al. Physical activity and public health: a recommendation from the Centers for Disease Control and Prevention and the American College of Sports Medicine. JAMA 1995;273:402-7.
  95. Schneider SH, Khachadurian AK, Amorosa LF, et al. Ten-year experience with exercise-based outpatient life-style modification program in the treatment of diabetes mellitus. Diabetes Care 1992;15:1800-10.
  96. American Diabetes Association. Diabetes mellitus and exercise. Diabetes Care 1998;21(Suppl 1):S40-4.
  97. Wasserman DH, Zinman B. Exercise in individuals with IDDM. Diabetes Care 1994;17:924-37.
  98. Tsui E, Zinman B. Exercise and diabetes — new insights and therapeutic goals. Endocrinologist 1997;5:263-71.
  99. Balfour JA, McTavish D. Acarbose: an update of its pharmacology and therapeutic use in diabetes mellitus. Drugs 1993;46:1025-54.
  100. Bell PM, Hadden DR. Metformin. Endocrinol Metab Clin North Am 1997;26:523-37.
  101. Davidson MB, Peters AL. An overview of metformin in the treatment of type 2 diabetes mellitus. Am J Med 1997;102:99-110.
  102. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989;321:1231-45.
  103. Groop LC. Sulfonylureas in NIDDM. Diabetes Care 1992;15:737-54.
  104. Henry RR. Thiazolidinediones. Endocrinol Metab Clin North Am 1997;26:553-73.
  105. Hermann LS, Schersten B, Melander A. Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination. Diabet Med 1994;11:953-60.
  106. Iwamoto Y, Kosaka K, Kuzuya T, et al. Effects of troglitazone: a new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy. Diabetes Care 1996;19:151-6.
  107. Lebovitz HE. Alpha-glucosidase inhibitors. Endocrinol Metab Clin North Am 1997;26:539-51.
  108. Lebovitz HE. Acarbose, an alpha-glucosidase inhibitor, in the treatment of non-insulin-dependent diabetes mellitus (NIDDM). Todays Ther Trends 1996;13:207-18.
  109. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997;26:511-22.
  110. United Kingdom Prospective Diabetes Study Group (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ 1995;310:83-8.
  111. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Group. N Engl J Med 1995;333:541-9.
  112. Chiasson JL, Josse RG, Hunt JA, et al. The efficacy of acarbose in the treatment of patients with non-insulin dependent diabetes mellitus. Ann Intern Med 1994:121:928-35.
  113. Heding LG, Marshall MO, Persson B, et al. Immunogenicity of monocomponent human and porcine insulin in newly diagnosed type 1 (insulin-dependent) diabetic children. Diabetologia 1984;27:96-8.
  114. Diabetes Control and Complications Trial Research Group. Implementation of treatment protocols in the Diabetes Control and Complications Trial. Diabetes Care 1995;18:361-76.
  115. Garg SK, Carmain JA, Braddy KC, et al. Pre-meal insulin analogue insulin lispro vs Humulin R insulin treatment in young subjects with type 1 diabetes. Diabet Med 1996;13:47-52.
  116. Pfutzner A, Kustner E, Forst T, et al. Intensive insulin therapy with insulin lispro in patients with type 1 diabetes reduces the frequency of hypoglycemic episodes. Exp Clin Endocrinol Diabetes 1996;104:25-30.
  117. Zinman B, Tildesley H, Chiasson JL, Tsui E, Strack T. Insulin lispro in CSII: results of a double-blind crossover study. Diabetes 1997;46:440-3.
  118. Shank ML, Del Prato S, DeFronzo RA. Bedtime insulin/daytime glipizide: effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995;44:165-72.
  119. Yki-Jarvinen H, Kauppila M, Kujansuu E, et al. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327:1426-33.
  120. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulfonylurea
    combination therapy in type II diabetes: a meta-analysis of the randomized placebo-controlled trials. Arch Intern Med 1996;156:259-64.
  121. Coniff RF, Shapiro JA, Seaton TB, et al. A double-blind placebo-controlled trial evaluating the safety and efficacy of acarbose for the treatment of patients with insulin-requiring type II diabetes. Diabetes Care 1995;18:928-32.
  122. Giugliano D, Quatraro A, Consoli G, et al. Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors. Eur J Clin Pharmacol 1993;44:107-12.
  123. Schwartz S, Raskin P, Fonseca V, Graveline JF. Efficacy of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. N Engl J Med 1998;338(13):861-6.
  124. Watkins PB, Whitcomb RW. Hepatic dysfunction associated with troglitazone. N Engl J Med 1998;38:916-7.
  125. Geffken G, Johnson SB, Silverstein J, et al. The death of a child with diabetes from neglect: a case study. Clin Pediatr 1992;31:325-30.
  126. Glasgow AM, Weissberg-Benchell J, Tynan WD, et al. Readmissions of children with diabetes mellitus to a children's hospital. Pediatrics 1991;88:98-104.
  127. Singer-Granick C, Hoffman RP, Kerensky K, et al. Glucagon responses to hypoglycemia in children and adolescents with IDDM. Diabetes Care 1988;11:643-9.
  128. Fairburn CG, Beglin SJ. Studies of the epidemiology of bulimia nervosa. Am J Psychiatry 1990;147:401-8.
  129. Koletzko S, Burgin-Wolff A, Koletzko B, et al. Prevalence of coeliac disease in diabetic children and adolescents: a multicentre study. Eur J Pediatr 1988;148:113-7.
  130. Frank M. Factors associated with non-compliance with a medical follow-up regimen after discharge from a pediatric diabetes clinic. Can J Diabetes Care 1996;20:13-20.
  131. Pacaud D, McConnell B, Huot C, et al. Transition from pediatric care to adult care for insulin-dependent diabetes patients. Can J Diabetes Care 1996;20:14-20.
  132. Bougneres PF, Landais P, Mairesse AM, et al. Improvement of diabetic control and acceptability of a three-injection insulin regime in diabetic adolescents. A multicenter controlled study. Diabetes Care 1993;16:94-102.
  133. Rovet JF, Ehrlich RM, Hoppe M. Intellectual deficits associated with early onset of insulin-dependent diabetes mellitus in children. Diabetes Care 1987;10:510-5.
  134. Ryan C, Vega A, Drash AL. Cognitive deficits in adolescents who developed diabetes early in life. Pediatrics 1985;75:921-7.
  135. Chase HP, Crews KR, Garg S, et al. Outpatient management vs in-hospital management of children with new-onset diabetes. Clin Pediatr (Phila) 1992;31:450-6.
  136. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994;43:960-7.
  137. Beks PJ, Mackay AJ, de Neeling JN, et al. Peripheral arterial disease in relation to glycaemic level in an elderly Caucasian population: the Hoorn Study. Diabetologia 1995;38:86-96.
  138. Morisaki N, Watanabe S, Kobayashi J, et al. Diabetic control and progression of in elderly patients: five-year follow-up study. J Am Geriatr Soc 1994;42:142-5.
  139. Kronsbein P, Jorgens V, Muhlhauser I, et al. Evaluation of a structured treatment and teaching programme on non-insulin-dependent diabetes. Lancet 1988;2:1407-11.
  140. Reaven GM. Beneficial effect of moderate weight loss in older patients with non-insulin-dependent diabetes mellitus poorly controlled with insulin. J Am Geriatr Soc 1985;33:93-5.
  141. Wilson W, Pratt C. The impact of diabetes education and peer support upon weight and glycemic control of elderly persons with noninsulin dependent diabetes mellitus (NIDDM). Am J Public Health 1987;77:634-5.
  142. Coulston AM, Mandelbaum D, Reaven GM. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1990;51:67-71.
  143. Skarfors ET, Wegener TA, Lithell H, et al. Physical training as treatment for type 2 (non-insulin-dependent) diabetes in elderly men: a feasibility study over 2 years. Diabetologia 1987;30:930-3.
  144. Asplund K, Wiholm BE, Lithner F. Glibenclamide-associated hypoglycaemia: a report on 57 cases. Diabetologia 1983;24:412-7.
  145. Tessier D, Dawson KG, Tetrault JP, et al. Glibenclamide vs gliclazide in type 2 diabetes of the elderly. Diabet Med 1994;11:974-80.
  146. Coscelli C, Calabrese G, Fedele D, et al. Use of premixed insulin among the elderly: reduction of errors in patient preparation of mixtures. Diabetes Care 1992;15:1628-30.
  147. Silverman BL, Rizzo TA, Cho NH. Long-term effects of the intrauterine environment: the Northwestern University Diabetes in Pregnancy Center. Diabetes Care 1998;(Suppl 2):B142-9.
  148. Pettit DJ, Knowler WC. Long-term effects of the intrauterine environment: birth weight and breast-feeding in Pima Indians. Diabetes Care 1998;(Suppl 2):B138-41.
  149. Miodovnik M, Mimouni F, Dignan PS, et al. Major malformations in infants of IDDM women: vasculopathy and early trimester poor gylcemic control. Diabetes Care 1998;21:713-8.
  150. Steel JM, Johnstone FD, Hepburn DA, et al. Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 1990;301:1070-4.
  151. Hanson U, Persson B, Thunell S. Relationship between haemoglobin A1c in early type 1 (insulin-dependent) diabetic pregnancy and the occurrence of spontaneous abortion and fetal malformation in Sweden. Diabetologia 1990;33:100-4.
  152. Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990;13:34-40.
  153. Reece EA, Coustan DR, Hayslett JP, et al. Diabetic nephropathy: pregnancy performance and fetomaternal outcome. Am J Obstet Gynecol 1988;159:56-66.
  154. Small M, Cassidy L, Leiper JM, et al. Outcome of pregnancy in insulin-dependent (type 1) diabetic women between 1971 and 1984. Q J Med 1986;61:1159-69.
  155. Pettitt DJ, Baird HR, Aleck KA, et al. Excessive obesity in offspring of Pima Indian women with diabetes during pregnancy. N Engl J Med 1983;308:242-5.
  156. Jovanovic L. American Diabetes Association's Fourth International Workshop Conference on Gestational Diabetes Mellitus: summary and discussion: therapeutic interventions. Diabetes Care 1998;21(52):B131-7.
  157. Langer O, Berkus M, Brustman L, et al. Rationale for insulin management in gestational diabetes mellitus. Diabetes 1991;40:186-90.
  158. De Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995;333:1237-41.
  159. Jovanovic-Peterson L, Durak EP, Peterson CM. Randomized trial of diet versus diet plus cardiovascular conditioning on glucose levels in gestational diabetes. Am J Obstet Gynecol 1989;161:415-9.
  160. Kaufmann RC, Schleyhahn RC, Huffman DG, et al. Gestational diabetes diagnostic criteria: long-term maternal follow-up. Am J Obstet Gynecol 1995;172:621-5.
  161. O'Sullivan JB, Mahan CM. Diabetes subsequent to the birth of a large baby: a 16-year prospective study. J Chronic Dis 1980;33:37-45.
  162. Delisle HF, Ekoe JM. Prevalence of non-insulin-dependent diabetes mellitus and impaired glucose tolerance in two Algonquin communities in Quebec. CMAJ 1993;148:41-7.
  163. Harris SB, Gittelsohn J, Hanley A, et al. The prevalence of NIDDM and associated risk factors in Native Canadians. Diabetes Care 1997;20:185-7.
  164. Macauley AC, Paradia G, Potvin L, et al. The Kahnawake Schools Diabetes Prevention Project: intervention, evaluation, and baseline results of a diabetes primary prevention program with a native community in Canada. Prev Med 1997;28:779-90.
  165. Dean HJ, Mundy RL, Moffat M. Non-insulin-dependent diabetes mellitus in Indian children in Manitoba. CMAJ 1992;147:52-7.
  166. Dean HJ. NIDDM-Y in First Nations children in Canada. Clin Pediatr (Phila) 1998;37:89-96.
  167. Fox C, Harris SB, Whalen-Brough E. Diabetes among Native Canadians in Northwestern Ontario: 10 years later. Chronic Dis Can 1994;15:92-6.
  168. Harris SB, Caulfield LE, Sugamori ME, et al. The epidemiology of diabetes in pregnant Native Canadians. Diabetes Care 1997;20:1422-5.
  169. Klein R, Klein BEK, Moss SE. Visual impairment in diabetes. Ophthalmology 1984;91:1-9.
  170. Klein R, Klein BEK, Moss SE. Epidemiology of proliferative diabetic retinopathy. Diabetes Care 1992;15:1875-91.
  171. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IV. Diabetic macular edema. Ophthalmology 1984;91:1464-74.
  172. Klein BEK, Klein R, Wang Q, et al. Older-onset diabetes and lens opacities. The Beaver Dam Eye Study. Ophthalmic Epidemiol 1995;2:49-55.
  173. Klein BEK, Klein R, Jensen SC. Open-angle glaucoma and older-onset diabetes: the Beaver Dam Eye Study. Ophthalmology 1994;101:1173-7.
  174. Tielsch JT, Katz J, Quigley HA. Diabetes, intraocular pressure, and primary open-angle glaucoma in the Baltimore Eye Study. Ophthalmology 1995;102:48-53.
  175. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. IX. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1989;107:237-43.
  176. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. X. Four-year incidence and progression of diabetic retinopathy when age at diagnosis is 30 years or more. Arch Ophthalmol 1989;107:244-9.
  177. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiology Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984;102:520-6.
  178. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiology Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984;102:527-32.
  179. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study report 22. Arch Ophthalmol 1996;114:1079-84.
  180. Klein R, Moss SE, Klein BEK, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XI. The incidence of macular edema. Ophthalmology 1989;96:1501-10.
  181. Early Treatment Diabetic Retinopathy Study Research Group. Grading diabetic retinopathy from stereoscopic color fundus photographs — an extension of the modified Airlie House classification. ETDRS report 10. Ophthalmology 1991;98:786-806.
  182. Moss SE, Klein R, Kessler SD, et al. Comparison between ophthalmoscopy and fundus photography in determining severity of diabetic retinopathy. Ophthalmology 1985;92:62-7.
  183. Nathan DM, Fogel HA, Godine JE, et al. Role of diabetologist in evaluating diabetic retinopathy. Diabetes Care 1991;14:26-33.
  184. Sussman EJ, Tsiaras WG, Soper KA. Diagnosis of diabetic eye disease. JAMA 1982;247:3231-4.
  185. Kinyoun J, Barton F, Fisher M, et al. Detection of diabetic macular edema: ophthalmoscopy versus photography. Early Treatment Diabetic Retinopathy Study report 5. Ophthalmology 1989;96:746-51.
  186. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS report 12. Ophthalmology 1991;98:823-33.
  187. Klein R, Klein BEK, Moss SE, et al. Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 1994;154:2169-78.
  188. Klein R, Klein BEK, Moss SE, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16.
  189. Moss SE, Klein R, Klein BEK. Ten-year incidence of visual loss in a diabetic population. Ophthalmology 1994;101:1061-70.
  190. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. ETDRS report 1. Arch Ophthalmol 1985;103:1796-806.
  191. Ferris FL. How effective are treatments for diabetic retinopathy? JAMA 1993;269:1290-1.
  192. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy: the second report of Diabetic Retinopathy Study findings. Ophthalmology 1978;85:82-106
  193. Ferris F. Early photocoagulation in patients with either Type 1 or Type 11 diabetes. Trans Am Ophthalmol Soc 1996;94:505-37.
  194. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 5. Arch Ophthalmol 1990;108:958-64.
  195. Diabetic Retinopathy Vitrectomy Study Research Group. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision: results of a randomized trial. Diabetic Retinopathy Vitrectomy Study report 3. Ophthalmology 1988;95:1307-20.
  196. Canadian Organ Replacement Registry. Annual report 1996. Ottawa: Canadian Institute for Health Information; 1996. Abstract.
  197. Krolewski AS, Warram JH, Freire MB. Epidemiology of late diabetic complications. A basis for the development and evaluation of preventive programs. Endocrinol Metab Clin North Am 1996;25:217-42.
  198. Incidence and causes of treated ESRD [abstract]. In: Annual report. Bethesda (Md): United States Renal Data System; 1995. p. 25-37.
  199. Borch-Johnsen K, Kreiner S. Proteinuria: value as predictor of cardiovascular mortality in insulin dependent diabetes mellitus. BMJ 1987;294:1651-4.
  200. Earle K, Walker J, Hill C, et al. Familial clustering of cardiovascular disease in patients with insulin-dependent diabetes and nephropathy. N Engl J Med 1992;326:673-7.
  201. Krolewski AS, Warram JH, Christlieb AR, et al. The changing natural history of nephropathy in type I diabetes. Am J Med 1985;78:785-94.
  202. Selby JV, Fitzsimmons SC, Newman JM, et al. The natural history and epidemiology of diabetic nephropathy. Implications for prevention and control. JAMA 1990;263:1954-60.
  203. Wang SL, Head J, Stevens L, et al. Excess mortality and its relation to hypertension and proteinuria in diabetic patients: the WHO multinational study of vascular disease in diabetes. Diabetes Care 1996;19:305-12.
  204. Almdal T, Norgaard K, Feldt-Rasmussen B, et al. The predictive value of microalbuminuria in IDDM. A five-year follow-up study. Diabetes Care 1994;17:120-5.
  205. Forsblom CM, Groop PH, Ekstrand A, et al. Predictive value of microalbuminuria in patients with insulin-dependent diabetes of long duration. BMJ 1992;305:1051-3.
  206. Mathiesen ER, Ronn B, Storm B, et al. The natural course of microalbuminuria in insulin-dependent diabetes: a 10-year prospective study. Diabet Med 1995;12:482-7.
  207. Messent JW, Elliott TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992;41:836-9.
  208. Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89-93.
  209. Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577-81.
  210. Viberti GC, Hill RD, Jarrett RJ, et al. Microalbuminuria as a predictor of clinical nephropathy in insulin-dependent diabetes mellitus. Lancet 1982;1:1430-2.
  211. Krolewski AS, Laffel LM, Krolewski M, et al. Glycosolated hemoglobin and the risk of microalbuminuria in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995;332:1251-5.
  212. Nelson RG, Knowler WC, Pettitt DJ, et al. Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 1991;151:1761-5.
  213. Poulsen PL, Hansen B, Amby T, et al. Evaluation of a dipstick test for microalbuminuria in three different clinical settings, including the correlation with urinary albumin excretion rate. Diabetes Metab 1992;18:395-400.
  214. Schwab SJ, Dunn FL, Feinglos MN. Screening for microalbuminuria. A comparison of single sample methods of collection and techniques of albumin analysis. Diabetes Care 1992;15:1581-4.
  215. Warram JH, Gearin G, Laffel LM, et al. Effect of duration of type I diabetes on the prevalence of stages of diabetic nephropathy defined by urinary albumin/creatinine ratio. J Am Soc Nephrol 1996;7:930-7.
  216. Beck-Nielsen H, Richelsen B, Mogensen CE, et al. Effect of insulin pump treatment for one year on renal function and retinal morphology in patients with IDDM. Diabetes Care 1985;8:585-9.
  217. Christensen CK, Christiansen JS, Schmitz A, et al. Effect of continuous subcutaneous insulin infusion on kidney function and size in IDDM patients: a 2 year controlled study. J Diabet Complications 1987;1:91-5.
  218. Dahl-Jorgensen K, Hanssen KF, Kierulf P, et al. Reduction of urinary albumin excretion after 4 years of continuous subcutaneous insulin-dependent diabetes mellitus. Acta Endocrinol (Copenh) 1988;117:19-25.
  219. Deckert T, Lauritzen T, Parving HH, et al. Effect of two years of strict metabolic functions in long term insulin-dependent diabetes. Diabet Nephropathy 1984;3:6-10.
  220. Lauritzen T, Frost-Larsen K, Larsen KF, et al. Two-year experience with continuous subcutaneous insulin infusion in relation to retinopathy and neuropathy. Diabetes 1985;34:74-9.
  221. Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993;329:304-9.
  222. Reichard P, Berglund B, Britz A, et al. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med 1991;230:101-8.
  223. Kroc Collaborative Study Group. Blood glucose control and the evolution of diabetic retinopathy and albuminuria. N Engl J Med 1984;311:365-72.
  224. Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993;341:1306-9.
  225. Laffel LM, McGill JB, Gans DJ. The beneficial effect of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. North American Microalbuminuria Study Group. Am J Med 1995;99:497-504.
  226. Mathiesen ER, Hommel E, Giese J, et al. Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria. BMJ 1991;303:81-7.
  227. Ravid M, Lang R, Rachmani R, et al. Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin-dependent diabetes mellitus: a 7-year follow-up study. Arch Intern Med 1996;156:286-9.
  228. Sano T, Kawamura T, Matsumae H, et al. Effects of long-term enalapril treatment on persistent microalbuminuria in well-controlled hypertensive and normotensive NIDDM patients. Diabetes Care 1994;17:420-4.
  229. Microalbuminuria Captopril Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587-93.
  230. Bjorck S, Mulec H, Johnsen SA, et al. Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992;304:339-43.
  231. Kasiske BL, Kalil RS, Ma JZ, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 1993;118:129-38.
  232. Lacourciere Y, Nadeau A, Poirer L, et al. Captopril or conventional therapy in hypertensive type II diabetics. Three-year analysis. Hypertension 1993;21:786-94.
  233. Lewis SB, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62.
  234. Liou HH, Huang TP, Campese VM. Effect of long-term therapy with captopril on proteinuria and renal function in patients with non-insulin-dependent diabetes and with non-diabetic renal diseases. Nephron 1995;69:41-8.
  235. Mathiesen ER, Borch-Johnsen K, Jensen DV, et al. Improved survival in patients with diabetic nephropathy. Diabetologia 1989;32:884-6.
  236. Mogenson CE. Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy. BMJ 1982;285:685-8.
  237. Nielsen FS, Rossing P, Gall MA, et al. Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects wtih diabetic nephropathy. Diabetes 1994;43:1108-13.
  238. Parving HH, Smidt UM, Hommel E, et al. Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy. Am J Kidney Dis 1993;22:188-95.
  239. Parving HH, Hommel E. Prognosis in diabetic nephropathy. BMJ 1989;299:230-3.
  240. Parving HH, Andersen AR, Smidt UM, et al. Early aggressive anti-hypertensive treatment reduces rate of decline in kidney function in diabetic nephropathy. Lancet 1983;1:1175-9.
  241. American Diabetes Association. Treatment of hypertension in diabetes. Diabetes Care 1996;19:S107-17.
  242. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 1994;17:616-23.
  243. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1993;16:S72-8.
  244. American Diabetes Association. Detection and management of lipid disorders in diabetes. Diabetes Care 1993;16:S106-12.
  245. Pedrini MT, Levey AS, Lau J, et al. The effect of dietary protein restriction on the progression of diabetic and non-diabetic renal diseases: a meta-anaylsis. Ann Intern Med 1996;124:627-32.
  246. Partanen J, Niskanen L, Lehtinen J, et al. Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1995;333:89-94.
  247. Max MB, Lynch SA, Muir J, et al. Effects of desipramine, amitriptyline and fluoxetine on pain in diabetic neuropathy. N Engl J Med 1992;326:1250-6.
  248. Max MB, Kishore-Kumar R, Schafer SC, et al. Efficacy of desipramine in painful diabetic neuropathy: a placebo-controlled trial. Pain 1991;45:1-9.
  249. Max MB, Culnane M, Schafer SC, et al. Amitriptyline relieves diabetic neuropathy pain in patients with normal or depressed mood. Neurology 1987;37:589-96.
  250. Young MJ, Breddy JL, Veves A, et al. The prediction of diabetic neuropathic foot ulceration using vibration perception thresholds: a prospective study. Diabetes Care 1994;17:557-60.
  251. Vinik AI, Suwanwalaikorn S, Stansberry KB, et al. Quantitative measurement of cutaneous perception in diabetic neuropathy. Muscle Nerve 1995;18:574-84.
  252. Diabetes Control and Complications Trial Research Group (DCCT). The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995;122:561-8.
  253. Gomez-Perez FJ, Rull JA, Dies H, et al. Nortriptyline and fluphenazine in the symptomatic treatment of diabetic neuropathy. A double-blind cross-over study. Pain 1985;23:395-400.
  254. McQuay H, Carroll D, Jadad AR, et al. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995;311:1047-52.
  255. Stracke H, Meyer UE, Schumacher HE, et al. Mexiletene in the treatment of diabetic neuropathy. Diabetes Care 1992;15:1550-5.
  256. Low PA, Opfer-Gehrking TL, Dyck PJ, et al. Double-blind, placebo-controlled study of the application of capsaicin cream in chronic distal painful polyneuropathy. Pain 1995;62:163-8.
  257. Capsaicin Study Group. Treatment of painful diabetic neuropathy with topical capsaicin. A multicenter, double-blind, vehicle-controlled study. Arch Intern Med 1991;151:2225-9.
  258. American Diabetes Association clinical practice recommendations 1997: foot care in patients with diabetes mellitus. Diabetes Care 1997;20(Suppl 1):1-70.
  259. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Diabetes in America. 2nd ed. Washington: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995. p. 409.
  260. Eastman RC. Neuropathy in diabetes. In: Diabetes in America. 2nd ed. Washington: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995. p. 339.
  261. Palumbo PJ, Melton LJ. Peripheral vascular disease and diabetes. In: Diabetes in America. 2nd ed. Washington: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995. p. 401.
  262. Boyko EJ, Lipsky BA. Infection and diabetes. In: Diabetes in America. 2nd ed. Washington: National Diabetes Data Group, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health; 1995. p. 485.
  263. Frykberg RD. Diabetic foot ulcerations. In: The high risk foot in diabetes mellitus. New York: Churchill Livingstone; 1991. p. 151.
  264. Frykberg RG, Veves A. Diabetic foot infections. Diabetes Metab Rev 1996;12:255-70.
  265. Gibbons GW, Eliopoulos GM, Kozak GP, et al. Infection of the diabetic foot. In: Kozak GP, Campbell DR, Frykberg RG, et al., editors. Management of diabetic foot problems. Philadelphia: Saunders; 1995. p. 121.
  266. Reiber GE, Pecoraro RE, Koepsell TD. Risk factors for amputation in patients with diabetes mellitus: a case control study. Ann Intern Med 1992;117:97-105.
  267. Bild DE, Selby JV, Sinnock P, et al. Lower-extremity amputation in people with diabetes: epidemiology and prevention. Diabetes Care 1989;12:24-31.
  268. Reiber GE. Epidemiology of the diabetic foot. In: Levin ME, O'Neal LW, Bowker JH, editors. The diabetic foot. St. Louis: Mosby; 1993. p. 1.
  269. Ebskov B, Josephsen P. Incidence of reamputation and death after gangrene of the lower extremity. Prosthet Orthot Int 1980;4:77-80.
  270. Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983;6:87-91.
  271. Diabetes surveillance, 1991. Washington: United States Dept of Health and Human Services; 1991. Abstract.
  272. Assal JP, Muhlhauser I, Pernet A, et al. Patient education as the basis for diabetes care in clinical practice and research. Diabetologia 1985;28:602-13.
  273. Litzelman DK, Slemenda CW, Langefeld CD, et al. Reduction of lower extremity clinical abnormalities in patients with non-insulin-dependent diabetes mellitus. A randomized controlled trial. Ann Intern Med 1993:119:36-41.
  274. Malone JM, Snyder M, Anderson G, et al. Prevention of amputation by diabetic education. Am J Surg 1989;158:520-4.
  275. Fuller JH, Elford J, Goldblatt P, et al. Diabetes mortality: new light on an underestimated public health problem. Diabetologia 1983;24:336-41.
  276. Garcia MJ, McNamara PM, Gordon T, et al. Morbidity and mortality in diabetics in the Framingham population. Sixteen year follow-up study. Diabetes 1974;23:105-11.
  277. Jarrett J. Mortality in diabetes. Q J Med 1990;75:413-4.
  278. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other risk factors, and 12-year cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16:434-44.
  279. Krolewski AS, Kosinski EJ, Warram JH, et al. Magnitude and determinants of coronary artery disease in juvenile-onset, insulin-dependent diabetes mellitus. Am J Cardiol 1987;59:750-5.
  280. Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979;241:2035-8.
  281. Kessler II. Mortality experience of diabetic patients: a twenty-six year follow-up study. Am J Med 1971;51:715-24.
  282. Lerner D, Kannel WB. Patterns of coronary heart disease morbidity and mortality in the sexes: a 26-year follow-up of the Framingham population. Am Heart J 1986;111:383-90.
  283. Nesto RW, Phillips RT, Kett KG, et al. Angina and exertional myocardial ischemia in diabetic and nondiabetic patients: assessment by exercise thallium scintigraphy. Ann Intern Med 1988;108:170-5.
  284. Scheidt-Nave C, Barrett-Connor E, Wingard DL. Resting electrocardiographic abnormalities suggestive of asymptomatic ischemic heart disease associated with non-insulin-dependent diabetes mellitus in a defined population. Circulation 1990;81:899-906.
  285. Weiner DA, Ryan TJ, Parsons L, et al. Significance of silent myocardial ischemia during exercise testing in patients with diabetes mellitus: a report from the Coronary Artery Surgery Study (CASS) Registry. Am J Cardiol 1991;68:729-34.
  286. Abbott RD, Donahue RP, Kannel WB, et al. The impact of diabetes on survival following myocardial infarction in men vs. women: the Framingham Study. JAMA 1988;260:3456-60.
  287. Zuanetti G, Latini R, Maggioni AP, et al. Influence of diabetes on mortality in acute myocardial infarction: data from the GISSI-2 study. J Am Coll Cardiol 1993;22:1788-94.
  288. Yudkin JS. How can we best prolong life? Benefits of coronary risk factor reduction in non-diabetic and diabetic subjects. BMJ 1993;306:1313-8.
  289. Downs JR, Beere PA, Whitney E, et al. Design and rationale of the Air Force/
    Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 1997;80(3):287-93.
  290. Antiplatelets Trialists Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:71-72, 81-106.
  291. Early Treatment Diabetic Retinopathy Study Research Group. Aspirin effects on mortality in patients with diabetes mellitus. JAMA 1992;268:1292-300.
  292. Early Treatment Diabetic Retinopathy Study Research Group. Effects of aspirin on treatment of retinopathy: ETDRS report 8. Ophthalmology 1991;98:
    757-65.
  293. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. The sixth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997;157:2413-46.
  294. Dawson KG, McKenzie JK, Ross SA, et al. Report of the Canadian Hypertension Society Consensus Conference: 5. Hypertension and diabetes. CMAJ 1993;149:821-6.
  295. Curb JD, Pressel SL, Cutler JA, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabeteic patients with isolated systolic hypertension. Systolic hypertension in the elderly program cooperative research group. JAMA 1996;276:1886-92.
  296. Estacio OE, Jeffers BW, Hiatt WR, et al. The effect of nisoldipine as compared to enalapril on cardiovascular outcomes in patients with non-insulin dependent diabetes and hypertension. N Engl J Med 1998;338:645-52.
  297. Tatti P, Pahor M, Byington RP, et al. Outcome results of the fosinopril versus amlodipine cardiovascular events randomized trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 1998;21:597-603.
  298. United Kingdom Prospective Diabetes Study Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes. (UKPDS 33). Lancet 1998;352:837-53.
  299. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes. (UKPDS 34). Lancet 1998;352:854-65.
  300. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 38). BMJ 1998;317:703-13.
  301. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes. (UKPDS 39). BMJ 1998;317:713-20.
  302. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes. (UKPDS 40). BMJ 1998;317:720-6.